Published online Mar 6, 2021. doi: 10.12998/wjcc.v9.i7.1705
Peer-review started: October 23, 2020
First decision: November 20, 2020
Revised: December 24, 2020
Accepted: January 6, 2021
Article in press: January 6, 2021
Published online: March 6, 2021
Core Tip: The coronavirus disease 2019 (COVID-19) is the word that certainly will not be forgotten by everybody who lives in the first half of the twenty-first century. It has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, there is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cells are widely used to treat tissue and organ injuries with effective immunomodulatory and repair capacities, which makes them ideal for allogenic adoptive transfer therapy. In this study, we describe the first confirmed case of COVID-19 in Hangzhou, China to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19, which can be helpful to find a promising therapeutic approach for this disease.